Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)

Novato, CA
AAV
Program data pending ClinicalTrials.gov matching
55.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)

Signal Score
55.0/100
Quality Compliance
Assessment pending
Headquarters
Novato, CA
Modalities
AAV
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesAAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 50.0
Manufacturing site information being gathered
Modalities: AAV
Capacity assessment: 50.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Manufacturing site information being gathered
Modalities: AAV
Capacity assessment: 50.0/100

Frequently Asked Questions About Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)

What is Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)'s CDMO Signal Score?
Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A) has a Signal Score of 55/100, based on quality, operations, financial stability, and capacity data.
Evaluating Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A) for a manufacturing program?
Use the free AI matchmaker to compare Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 85.6
Oligonucleotide, Biologics, AAV
August Bioservices
San Carlos, CA
Signal Score: 77.4
AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA